Plaintiff
5 cases as plaintiff.
Medivation Prostate Therapeutics LLC is a subsidiary of the global pharmaceutical company Pfizer Inc. It was originally formed as a subsidiary of Medivation, Inc., a biopharmaceutical company founded in 2003. In a deal largely driven by the value of its main drug asset, Pfizer acquired the parent company, Medivation, Inc., in September 2016 for approximately $14 billion. As a result, Medivation Prostate Therapeutics became a wholly-owned subsidiary of Pfizer.
The company's operations and value are centered on the intellectual property for the blockbuster prostate cancer drug Xtandi (enzalutamide). Xtandi, an androgen receptor inhibitor, was developed by Medivation in partnership with the Japanese pharmaceutical company Astellas Pharma Inc. and first received FDA approval in 2012 for treating metastatic castration-resistant prostate cancer. Medivation Prostate Therapeutics LLC appears to be the legal entity that holds the patents covering this key oncology drug.
The company's patent litigation posture is that of a brand-name pharmaceutical manufacturer protecting its key product from generic competition. As shown in the case data, Medivation Prostate Therapeutics has acted as a plaintiff in all five of its tracked lawsuits, with zero cases as a defendant. This pattern is characteristic of Hatch-Waxman litigation, where patent holders sue companies that file Abbreviated New Drug Applications (ANDAs) seeking to market generic versions of a patented drug. All of its tracked cases have been filed in the U.S. District Court for the District of New Jersey, a common venue for pharmaceutical patent disputes.
The tracked cases are all related to defending the patent portfolio for Xtandi. The lawsuits are filed in partnership with co-plaintiff Astellas Pharma, Medivation's development and commercialization partner. The defendants, including Dr. Reddy's Laboratories, Hikma Pharmaceuticals, and Zydus Pharmaceuticals, are all generic drug manufacturers. This litigation is a direct effort to enforce the patent rights acquired in the $14 billion purchase of Medivation and to protect the market exclusivity of Xtandi.
Watchlist
Email-only, free, anonymous. We'll notify you when Medivation Prostate Therapeutics LLC files another patent-infringement lawsuit. One-click unsubscribe from any alert.
The accused products are generic versions of Xtandi 40 mg and 80 mg tablets.
The claims and counterclaims in this case were dismissed with prejudice, with each party bearing its own costs.
This case has been consolidated with case 3:24-cv-09748 for all purposes. An amended complaint including the '628 patent was filed on January 3, 2025, and the case appears to be ongoing.
This case has been consolidated with case 3:24-cv-09403 and appears to be ongoing. An amended complaint including US patent 12161628 was filed on January 3, 2025.
This case is part of the broader litigation surrounding generic versions of the drug Xtandi® (enzalutamide), involving US Patent 11,839,689.